Abstract We report an in silico method to screen for receptors or pathways that could be targeted to elicit beneficial transcriptional changes in a cellular model of a disease of interest. In our method, we integrate: (1) a dataset of transcriptome responses of a cell line to a panel of drugs; (2) two sets of genes for the disease; and (3) mappings between drugs and the receptors or pathways that they target. We carried out a gene set enrichment analysis (GSEA) test for each of the two gene sets against a list of genes ordered by fold-change in response to a drug in a relevant cell line (HL60), with the overall score for a drug being the difference of the two enrichment scores. Next, we applied GSEA for drug targets based on drugs that have been ranked by their differential enrichment scores. The method ranks drugs by the degree of anti-correlation of their gene-level transcriptional effects on the cell line with the genes in the disease gene sets. We applied the method to data from (1) CMap 2.0; (2) gene sets from two transcriptome profiling studies of atherosclerosis; and (3) a combined dataset of drug/target information. Our analysis recapitulated known targets related to CVD (e.g., PPARc; HMG-CoA reductase, HDACs) and novel targets (e.g., amine oxidase A, d-opioid receptor). We conclude that combining disease-associated gene sets, drug-transcriptome-responses datasets and drug-target annotations can potentially be useful as a screening tool for diseases that lack an accepted cellular model for in vitro screening.
Introduction
Due to functional pleiotropy of drug targets and polypharmacological drug-target mechanisms, many approved drugs likely have undiscovered therapeutic applications. In light of the significant cost-efficiencies of bringing an already approved drug to market under a new indication (i.e., drug repositioning; [1] ), the recent availability of comprehensive transcriptome profiling data for the effects of drugs on cell lines [2] has spurred interest in computationally screening for new indications for existing drugs, i.e., in silico drug repositioning [3] .
Cardiovascular diseases (CVD) and their main underlying pathology, the chronic inflammatory disease atherosclerosis, are together the leading cause of death. To the extent that current lipid-lowering drugs for CVD prevention are estimated to reduce CVD mortality by only 20 % [4] , there is a need for new therapeutic approaches. Atherosclerosis is particularly attractive for a computational approach because there is not a natural in vitro cellular assay for drug-tophenotype screening for this disease. A key cellular constituent in atherosclerotic plaque, the macrophage (an innate immune cell of the myeloid lineage), is both an enticing therapeutic target and has an analogous human myeloid cell line, HL60, that is a workhorse cell line in pharmacology related to hematopoiesis [5] .
In this work, we investigated whether candidate atheroprotective or cardioprotective drugs can be identified by applying a rank-based statistical test (gene set enrichment analysis or GSEA; [6] ) to measurements of druginduced differential expression of atherosclerosis-related genes (''gene sets'') in a physiologically relevant human cell line. For the transcriptome profiling data on cell line drug responses, we used measurements from the Connectivity Map 2.0 (CMap2) database [2] for differential expression of 12,135 genes in HL60 cells that were treated with vehicle or one of 1229 drugs. We used CVD-related gene sets from two transcriptome studies of human tissues: a study comparing three types of atherosclerotic arteries (aorta, coronary, and carotid) with normal arteries [7] (Cagnin et al., 161 genes), and a study comparing unstable versus stable carotid plaques as determined by specific molecular markers [8] (Puig et al., 1271 genes). Thus, our analysis included four sets of genes; two for genes that are up-or downregulated in atherogenesis, and two for genes that are up-or downregulated as plaque becomes unstable. Using the gene sets and the CMap2 data, we screened for drugs that reduced HL60 expression of genes in the ''upregulated'' gene sets and increased expression of genes in the ''downregulated'' gene sets, as measured by enrichment scores. We used a novel permutation-based approach to assess the significance of each enrichment score. We based our choice of weight factor for the analysis on accuracy results that we obtained by applying GSEA and a weighted Kolmogorov-Smirnov test with various weights to simulated data (the first such analysis of which we are aware).
Materials and Methods

Connectivity Map Analysis
We obtained probe intensity files (CEL files; Affymetrix HG-U133A and HT_HG-U133A GeneChips) for HL60 experiments spanning 1229 drugs (1406 files in all) from the Connectivity Map 2.0 website (broadinstitute.org/cmap). We mapped probe intensities to 12,135 probesets using the Entrez Gene-based probesets from the University of Michigan Custom CDF project (brainarray.mbni.med.umich.edu) release 18.0.0, and we obtained probeset-level intensities using the justRMA function in the Bioconductor software package ''affy.'' For each comparison of a drug to vehicle, we selected only probesets for which the within-sample-group-average log 2 intensity is at least six (the background hybridization signal level) in either the drug or vehicle sample group. For each probeset, we computed the average log 2 ratio of the intensity in drugtreated to vehicle-treated HL60 cells. Then, for each drug, we ranked all above-background probesets (genes) based on their log 2 ratios. All subsequent analyses were carried out in the R statistical computing environment.
Synthetic Dataset Analysis to Determine
Optimal Weighting
For the synthetic dataset analysis, we generated 1000 ''positive'' gene set ranks and 1000 ''control'' gene set ranks (each of size 80 genes). For both types of gene sets, rank assignments were randomly sampled from {1, …, 1229} without replacement. Rank assignments were selected with uniform probability for the case of a ''control'' gene set, and rank assignments for ''positive'' gene sets were selected with a bias probability for rank j defined by
where the values of q tested were 0.1, 0.2, 0.3, and 0.4. Expression ratios r j for the set of 8000 genes were obtained from the average log 2 ratios at each rank, across all drugs. The enrichment score E was computed for each of the 1000 gene sets, and gene sets were ordered by the E scores, and the area under the sensitivity versus false positive error rate (i.e., area under the receiver operating characteristic) curve was computed using the ROCR software package.
Selection of Disease-Associated Gene Sets
We obtained genes from Table S2 of the Cagnin et al. article [7] that were classified as ''up'' (64 genes) or ''down'' (97 genes), for the gene sets for coronary artery disease versus normal arteries. From Table S3 of the Puig et al. study [8] , we selected genes that were classified as ''inflamed'' (900 genes) for the ''up'' gene set, and genes that were classified as ''stable'' (371 genes) for the ''down'' gene set. In both cases, genes were selected based on the differential expression analysis in the original study (FDR \ 0.05 for the Cagnin et al. study and FDR \ 0.12 for the Puig et al. study). The HGNC identifiers from the Cagnin et al. and the Puig et al. studies were converted to Entrez Gene identifiers using the web-based tool DAVID (david.ncifcrf.gov).
Permutation Method for Computing P values
For each drug and gene set resulting in a E score, we computed E (random) scores for 1000 randomly generated gene sets. For each random gene set, the genes' ranks were sampled (uniform probability, no replacement). We computed the empirical P value of E as the cCDF of E in the distribution of E (random), using kernel density estimation (kCDF function in the sROC R package). For each pair of gene sets, a P value cutoff was determined at which the estimated false discovery rate would be 0.05 [9] . The resulting P value cutoffs for the gene set pairs based on the Cagnin et al. [7] and the Puig et al. [8] gene sets were P = 0.017 and P = 0.03, respectively.
TTD and DrugBank Databases
Drug-target data matrices were downloaded from two databases, DrugBank and Therapeutic Target Database (TTD), and matched to the drugs from the Connectivity Map. Drugs were matched using two different strategies, by its given name and by its CAS number. CAS number for each drug from the Connectivity Map was collected from DrugBank, Sigma-Aldrich and ChemSpider websites. Overall, 525 of 1087 drugs matched to DrugBank's database and 568 of 1087 matched to TTD's database. When combined, 604 of 1087 drugs were mapped to at least one target. Each drug target that was associated with at least three drugs was tested against the ranked list of drugs using GSEA.
Results and Discussion
Our method (Fig. 1 ) entails generating an overall disease association score DE for a given drug, based on two diseaserelated gene sets S up and S down and based on the expression log 2 -ratios r i of N genes (i 2 f1; . . .; Ng) in drug-treated versus vehicle-treated cells, where g j 2 f1; . . .; Ng is the gene whose expression log 2 ratio r g j has rank j (rank 1 means highest positive log 2 ratio), as described below. For each gene set S (where S is either the set S up for genes that are upregulated in disease versus normal tissue, or the gene set S down for genes that are downregulated in disease), we compute a weighted enrichment statistic E(S) by computing, for all i 2 f1; . . .; N ¼ jSjg,
where w ! 0 is the weight factor for the expression ratio, the case z = 0 corresponds to the GSEA method, the case z = 1 corresponds to a weighted Kolmogorov-Smirnov test, and where the normalization factors N M and N R are defined by 
We compute the enrichment score E(S) by the maximum deviation from zero,
The overall drug-to-disease association score is the difference in the enrichment score between the two diseaseassociated gene sets,
Based on uncertainty in the literature regarding the optimal selection of the per-gene weight factor w for the statistical test (where w = 0 corresponds to the unweighted test) and on whether the unweighted test (z = 0) is more accurate than a weighted Kolmogorov-Smirnov (WKS) or weighted GSEA test (z = 1) [6] , we simulated drug-response data and gene-set rankings under the null hypothesis (i.e., that the gene set is unrelated to the drug response) and under the alternate hypothesis (see Materials & Methods). We found that the unweighted GSEA (i.e., z = 0, w = 0) test was the most accurate (P \ 10 -4 for all pairwise comparisons with unweighted GSEA; Table 1 ), and thus we chose w = 0 and z = 0 as the parameter values.
To rank drugs by their potential therapeutic benefit in the context of a specific pathophysiological process (SPP) (atherogenesis for the Cagnin et al. gene sets; plaque destabilization for the Puig et al. gene sets) [7, 8] , we used a drug's DE score and P value. Specifically, for each SPP, we ranked drugs by their DE values, such that a top-ranked drug would have effects on HL60 cells that are the most anti-correlated with the ''directions'' of the gene sets for the SPP. ). Shown here are the results for the rank bias parameter value q = 0.2 (see Materials and Methods), but the relative accuracy results using all other values of q were consistent with the above results Table 2 Ten top-ranked drugs based on our drug repositioning screen using measured drug responses in HL60 cells Additionally, for each drug and gene set, we tested the null hypothesis that there is no association between the gene set and the drug response by computing E for the gene set for randomly permuted gene ranks, from which we empirically determined a P value. We eliminated any drug whose P values for both of the atherogenesis [7] gene sets did not satisfy P \ 0.017 or whose P values for both of the destabilization [8] sets did not satisfy P \ 0.03 (reflecting the latter SPP's larger gene set size). For each remaining drug, we averaged its ranks for the two SPPs (atherogenesis and plaque destabilization) to obtain an overall drug ranking; the top ten drugs are shown in Table 2 (the complete set of quantitative results for all drugs is provided as Online Resource 1). Based on the observation that the two top-scoring drugs share a common mechanism (histone deacetylase inhibition), we investigated whether there are other drug-target receptors or pathways that are enriched among the topscoring drugs. For each drug, we obtained its list of annotated target receptors and pathways, based on information from two databases, DrugBank [10] and TTD [11] . We then applied the unweighted GSEA method to the ranks of drugs that are associated with a specific target, versus the ranks of the complete set of drugs, to obtain an E score for the drug target (i.e., the receptor or pathway). The top-scoring drug targets (Table 3) include PPARc (whose pharmacological activation has been shown to reduce heart attacks [12] ) and HMG-CoA reductase (the rate-limiting enzyme in cholesterol biosynthesis, and the primary target of the statin class of drugs for CVD prevention and treatment; this finding is also consistent with reports that statins exert anti-inflammatory effects in macrophages [13] ). Other specific molecular targets, like amine oxidase [14] , cAMP and cAMP-inhibited cGMP 3 0 ,5 0 -cyclic phosphodiesterase 10A [15] , and phospholipase A2 [16] , are also reported to have roles in atherosclerosis.
Conclusions
Our finding that two of the top-scoring drugs (ranked by their transcriptional effects in HL60 cells) are HDAC inhibitors is intriguing in light of the broad range of pathophysiological processes that involve HDACs in CVD [17, 18] . Of relevance to atherosclerosis, in macrophages, regulation of cholesterol metabolic enzymes in response to statins is mediated by HDAC repression that can be recapitulated by trichostatin A treatment [19] . More generally, HDACs have been reported to have anti-inflammatory effects on macrophages [20] . The other HDAC inhibitor, valproic acid, has recently been demonstrated to attenuate atherosclerosis in a mouse model [21] . While in this example application of our approach, we analyzed the effects of drugs on expression levels of protein-coding genes, our approach could in principle be readily applied to screen for drugs that modulate expression levels of disease-associated microRNAs (which are of significant interest in drug discovery for cancer and other diseases [22] [23] [24] using data from a drug-microRNA expression database such as Pharmaco-miR [25] .
Our analysis shows that our computational approach, including the novel permutation test that we have introduced, is both practical and effective for identifying novel potential drugs and drug targets for two pathophysiological processes related to CVD (atherosclerosis and plaque destabilization). Our work also provides evidence in support of using unweighted GSEA for in silico drug screening, and our overall computational approach is readily applicable to other disease contexts. 
